MorphoSys is a late-stage, biopharmaceutical company devoted to the development of innovative therapies for patients suffering from serious diseases.
MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are in clinical development.
The broad pipeline spans MorphoSys's two business segments: Proprietary Development, in which MorphoSys invests in its own product candidates, and Partnered Discovery, in which product candidates are developed for Pharma and Biotech partners.
Tremfya®, marketed by Janssen, became the first therapeutic antibody based on MorphoSys's proprietary technology to receive marketing approval for the treatment of plaque psoriasis.
Morphosys is headquartered in Munich and has a fully owned U.S. subsidiary with the primary focus to build capabilities in preparation for the planned U.S. commercialization of MOR208.
MorphoSys is listed on the Frankfurt Stock Exchange and on the Nasdaq.
Ylanthia® is our newest antibody library, which comprises over 100 billion fully human antibodies. Novel scaffolds & bispecifics – MorphoSys’s technology portfolio also contains (a) certain peptidic formats based on the lanthipeptide platform, a source of stabilized peptides, and (b) a novel peptidic scaffold, as well as (c) bispecific formats / effector functions. MOR208, a humanized, Fc engineered, monoclonal anti-CD19 antibody.
MorphoSys is developing MOR208 in multiple combination trials in lymphomas. MOR202 is currently under clinical investigation in patients with relapsed or refractory multiple myeloma.
MOR210 is MorphoSys's proprietary, preclinical-stage antibody directed against C5aR, which has potential to be developed as an immuno-oncology agent.
MOR106, originating from a co-development with Galapagos and currently in phase 2 development in atopic dermatitis, is the first antibody from MorphoSys’s Ylanthia platform in clinical development.
A humanized, Fc engineered, monoclonal anti-CD19 antibody. MorphoSys is developing MOR208 in multiple combination trials in lymphomas. Current focus is on bringing this drug candidate to market as quickly as possible in relapsed/refractory DLBCL with two ongoing combination trials: The phase 3 “B-MIND” trial evaluating MOR208 plus bendamustine vs. rituximab plus bendamustine and a phase 2 “L-MIND” trial evaluating MOR208 plus lenalidomide. Additional indications are being explored.
MOR202 is currently under clinical investigation in patients with relapsed or refractory multiple myeloma. Following our first regional licensing and commercialization partnership with I-Mab for Greater China, we explore partnerships for additional territories and plan to evaluate the compound’s potential activity in one or more non-oncology indications either alone or together with a partner.
MOR210 is MorphoSys' proprietary, preclinical-stage antibody directed against C5aR, which has potential to be developed as an immuno-oncology agent. End of 2018, MorphoSys and I-Mab have entered into an exclusive strategic collaboration and regional licensing agreement for MOR210. We are open to explore additional partnerships which facilitate and/or broaden MOR210’s development and commercialization.